Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 31;12(2):546-565.
doi: 10.1093/advances/nmaa104.

Roles of the Polyphenol-Gut Microbiota Interaction in Alleviating Colitis and Preventing Colitis-Associated Colorectal Cancer

Affiliations
Review

Roles of the Polyphenol-Gut Microbiota Interaction in Alleviating Colitis and Preventing Colitis-Associated Colorectal Cancer

Yiying Zhao et al. Adv Nutr. .

Abstract

Accumulating evidence indicates that the gut microbiota can promote or inhibit colonic inflammation and carcinogenesis. Promotion of beneficial gut bacteria is considered a promising strategy to alleviate colonic diseases including colitis and colorectal cancer. Interestingly, dietary polyphenols, which have been shown to attenuate colitis and inhibit colorectal cancer in animal models and some human studies, appear to reach relatively high concentrations in the large intestine and to interact with the gut microbial community. This review summarizes the modulatory effects of polyphenols on the gut microbiota in humans and animals under healthy and diseased conditions including colitis and colitis-associated colorectal cancer (CAC). Existing human and animal studies indicate that polyphenols and polyphenol-rich whole foods are capable of elevating butyrate producers and probiotics that alleviate colitis and inhibit CAC, such as Lactobacillus and Bifidobacterium. Studies in colitis and CAC models indicate that polyphenols decrease opportunistic pathogenic or proinflammatory microbes and counteract disease-induced dysbiosis. Consistently, polyphenols also change microbial functions, including increasing butyrate formation. Moreover, polyphenol metabolites produced by the gut microbiota appear to have anticancer and anti-inflammatory activities, protect gut barrier integrity, and mitigate inflammatory conditions in cells and animal models. Based on these results, we conclude that polyphenol-mediated alteration of microbial composition and functions, together with polyphenol metabolites produced by the gut microbiota, likely contribute to the protective effects of polyphenols on colitis and CAC. Future research is needed to validate the causal role of the polyphenol-gut microbiota interaction in polyphenols' anti-colitis and anti-CAC effects, and to further elucidate mechanisms underlying such interaction.

Keywords: 16S rRNA; chemoprevention; colitis; colitis-associated colorectal cancer; gut microbiota; polyphenol; probiotics; short-chain fatty acids.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Roles of the polyphenol–gut microbiota interaction in polyphenols’ protective effects against colitis and colitis-associated colorectal cancer. The interaction between polyphenols and the gut microbiota can modulate gut microbial composition and functions. Specifically, polyphenols may promote butyrate producers and suppress pathogenic bacteria, which may lead to the increase in SCFAs and suppression of epithelial invasiveness, respectively. Additionally, gut microbes metabolize polyphenols into absorbable metabolites, which have been shown to have anticancer and anti-inflammatory activities and provide protection of gut barrier functions. These activities contribute to polyphenols’ disease-alleviation effects in animals and humans. MAPK, mitogen-activated protein kinase.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. - PubMed
    1. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14(25):3937–47. - PMC - PubMed
    1. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19(4):789–99. - PubMed
    1. Sobczak M, Wlazłowski M, Zatorski H, Sałaga M, Fichna J. Current overview of colitis-associated colorectal cancer. Open Life Sci. 2014;9(11):1022–9.. doi: 10.2478/s11535-014-0345-7.
    1. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–14 e5. - PubMed

Publication types